Delivering the promise of the Decade of Vaccines: Opportunities and challenges in the development of high quality new vaccines

Keith, Jacqueline A.; Bigger, Laetitia Agostini; Arthur, Phyllis A.; Maes, Edith; Daems, Rutger

doi:10.1016/j.vaccine.2012.12.032

Cited by 21 publications

(24 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although such programs undoubtedly draw essential attention and much-needed resources to vaccine development for neglected diseases, the so-called productivity gap, where industry-invested resources do not match the expected product return [99], is a significant impediment to this process. The process of differential pricing, whereby companies charge wealthier countries a higher price for a particular vaccine to offset the revenue loss associated with provision of that same vaccine to resource-poor nations, has allowed several vaccines to achieve a worldwide distribution [100]. However, the success of such a tiered pricing scheme depends entirely upon the magnitude and demographics of the target population in the developed nations.…”

Section: Essential Vaccine Considerationsmentioning

confidence: 99%

Current status of syphilis vaccine development: Need, challenges, prospects

Cameron¹,

Lukehart²

2014

Vaccine

View full text Add to dashboard Cite

Syphilis is a multistage disease caused by the invasive spirochete Treponema pallidum subsp. pallidum. Despite inexpensive and effective antibiotic therapy, syphilis remains a prevalent disease in developing countries and has re-emerged as a public health threat in developed nations. In addition to the medical burden imparted by infectious syphilis, congenital syphilis is considered the most significant infectious disease affecting fetuses and newborns worldwide, and individuals afflicted with syphilis have an enhanced risk for HIV transmission and acquisition. The global disease burden of syphilis and failure of decades of public health efforts to stem the incidence of disease highlight the need for an effective syphilis vaccine. Although challenges associated with T. pallidum research have impeded understanding of this pathogen, the existence of a relevant animal model has enabled insight into the correlates of disease protection. Complete protection against infection has been achieved in the animal model using an extended immunization regimen of γ-irradiated T. pallidum, demonstrating the importance of treponemal surface components in generation of protective immunity and the feasibility of syphilis vaccine development. Syphilis is a prime candidate for development of a successful vaccine due to the (1) research community’s accumulated knowledge of immune correlates of protection; (2) existence of a relevant animal model that enables effective pre-clinical analyses; (3) universal penicillin susceptibility of T. pallidum which enhances the attractiveness of clinical vaccine trials; and (4) significant public health benefit a vaccine would have on reduction of infectious/congenital syphilis and HIV rates. Critical personnel, research and market gaps need to be addressed before the goal of a syphilis vaccine can be realized, including recruitment of additional researchers to the T. pallidum research field with a proportional increase in research funding, attainment of a definitive understanding of correlates of protection in humans, and engagement of industry/funding partnerships for syphilis vaccine production.

show abstract

Section: Essential Vaccine Considerationsmentioning

confidence: 99%

Current status of syphilis vaccine development: Need, challenges, prospects

Cameron¹,

Lukehart²

2014

Vaccine

View full text Add to dashboard Cite

show abstract

“…The production of multicomponent vaccines indicates a considerable state interest in organizing and conducting vaccination, as well as its willingness to spend significant resources in this healthcare branch due to the fact that the production of vaccines is much less lucrative than, for example, of antibiotics [11,14,16]. Therefore, the next stage of our study was the structural analysis of countries-manufacturers of monovaccines and multicomponent vaccines registered in Ukraine, the results of which are given in Table, Fig.…”

Section: Resultsmentioning

confidence: 99%

Analysis of the assortment of immunobiological medical products used for children routine immunization at the Ukrainian pharmaceutical market

Slobodyanyuk¹,

Kononenko²

2015

Vìsn. farm.

View full text Add to dashboard Cite

show abstract

“…Although the resulting undervaluation bias may not have had important practical implications for well-established and low-cost vaccinations, such as those in the World Health Organization (WHO)'s Expanded Program on Immunization, it will likely guide policy makers toward underinvestment in expanding coverage with a new generation of more costly vaccinations, such as those against rotavirus, pneumococcal disease, and HPV-to the peril of the populations whose health and welfare these vaccinations could improve. A harder to estimate but potentially even more detrimental effect of systematic vaccination undervaluation is underinvestment in discovery and development of new vaccines (68). Potential market size is an important motivator for private industry to develop new products (69)(70)(71); adoption of vaccinations into national immunization plans will thus be a powerful signal to industry that could influence research investment decisions (68).…”

Section: Discussionmentioning

confidence: 99%

Valuing vaccination

Bärnighausen

Bloom

Cafiero-Fonseca

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

166

149

View full text Add to dashboard Cite

Vaccination has led to remarkable health gains over the last century. However, large coverage gaps remain, which will require significant financial resources and political will to address. In recent years, a compelling line of inquiry has established the economic benefits of health, at both the individual and aggregate levels. Most existing economic evaluations of particular health interventions fail to account for this new research, leading to potentially sizable undervaluation of those interventions. In line with this new research, we set forth a framework for conceptualizing the full benefits of vaccination, including avoided medical care costs, outcome-related productivity gains, behavior-related productivity gains, community health externalities, community economic externalities, and the value of risk reduction and pure health gains. We also review literature highlighting the magnitude of these sources of benefit for different vaccinations. Finally, we outline the steps that need to be taken to implement a broad-approach economic evaluation and discuss the implications of this work for research, policy, and resource allocation for vaccine development and delivery.benefit-cost analysis | immunization

show abstract

Delivering the promise of the Decade of Vaccines: Opportunities and challenges in the development of high quality new vaccines

Cited by 21 publications

References 8 publications

Current status of syphilis vaccine development: Need, challenges, prospects

Current status of syphilis vaccine development: Need, challenges, prospects

Analysis of the assortment of immunobiological medical products used for children routine immunization at the Ukrainian pharmaceutical market

Valuing vaccination

Contact Info

Product

Resources

About